## Description:

**Depression Screening Market Information: By Disease Type (Anxiety, Mood Disorders and Other Mental and Behavioral & Disorders), Diagnosis (Psychological Test, Lab Tests), Treatment (Medication,) and End User - Global Forecast till 2023**

### Intended Audience
- Pharmaceutical Companies
- Medical Devices Manufacturer
- Research and Development (R&D) Companies
- Market Research and Consulting Service Providers
- Potential Investors

### Market Scenario

Depression and mental health are the leading cause of disability and ill health across the globe. Depression affects an estimated one in 15 adults every year and also affects one in six people will experience depression at some time in their life. Depression can strike at any age but on average it appears during the late teens to mid-20s. Women are more likely than men to experience these depression related disorders. According to the latest estimations from (World Health Organization) WHO, more than 300 million people are now living having depression with an increase of more than 18% between 2005 and 2015. Depression is a kind of mental condition that causes individuals to experience depressed mood, loss of interest, feelings of low self-worth, disturbed sleep or appetite, low energy, and poor concentration. An individual who is suffering from depression experiences intense emotions of anxiety, hopelessness, negativity and helplessness.

Increasing prevalence of various mental disorder is one of the major driver for the market growth. Furthermore, rising funding for R&D and clinical trials are also supporting the growth of the market. Moreover, growing awareness of disorders and treatments, rapid adoption of new therapies and treatments, and technological advancement are key drivers for the market.

However, low public awareness of mental disorders and treatments in emerging nations and cultural stigma are the two major factors hindering the growth of the market.

According to a research, the mental disorders are the second leading cause of morbi-mortality in developing countries, besides that 86 of global suicides occur in low and middle income countries, which has result in low market growth.

The global depression screening market is expected to grow at a CAGR of 6.20% during the forecast period 2017-2023.

### Research Methodology
Segmentation

The global depression screening market is segmented on the basis of disease type, diagnosis, treatment, and end user.

On the basis of the disease type, it is further segmented into anxiety, mood disorders, depression, bipolar disorders, psychotic disorders, eating disorders and other mental and behavioral & disorders.

On the basis of the diagnosis, the market is segmented into psychological test, Lab tests, depression screening tests and others.

On the basis of the treatment, the market is segmented into medication (anti-anxiety medications, antidepressants, antipsychotic medications, stimulants, anti-seizures medications and others), brain-stimulation treatments (Vagus Nerve Stimulation (VNS), repetitive Transcranial Magnetic Stimulation (rTMS), Magnetic Seizure Therapy (MST), and Deep Brain Stimulation (DBS)), substance abuse treatment and others.

On the basis of the end user, the market is segmented into hospitals and clinics, medical research centers, academic institutes, and others.

Figure: Global Depression screening Market, by Disease Type, 2016 (%)
Europe is the second largest depression screening market. The growth of the depression screening market is attributed majorly due to increasing stress and changing lifestyle. In Europe, Germany is the largest market, while France and U.K are the second and third largest markets in the Europe. The growth of the market in Germany is attributed to rising awareness for diagnosis of the mental disorders and increasing focus on R&D activities. Moreover, flourishing growth of the medical device and pharmaceutical industry and emphasis on product differentiation also influence the growth of the market.

Asia Pacific is expected to be the fastest growing depression screening market owing to more number of developing nations in this region. Moreover, increasing prevalence of mental disorders, rapidly changing healthcare sector resulting in growth of the market.

The Middle East & Africa is expected to account for the least market share due to less availability of medical facilities and less development in the healthcare domain. However, countries like Qatar, Kuwait are focusing more on the healthcare domain and increasing medical facilities, which may boost the market growth in this region.

Key Findings:

On the basis of disease type, anxiety is the largest segment and continue to grow with the rate of 5.14% during the forecast period. While depression is the fastest growing segment and is projected to grow at a CAGR of 6.63% from 2016-2023.

On the basis of diagnosis, psychological test is the most widely used diagnostic test in depression screening protocol and is expected to reach USD 1,647.6 million in the year 2023 from USD 1,059.6 million in 2016.

On the basis of treatment, medications is the fastest growing market, which is expected to reach USD 1,949.2 million by 2023.

Key Players

Some of the key players in this market are Alkermes (Republic of Ireland), ALLERGAN (Republic of Ireland), AstraZeneca (UK), Bristol-Myers Squibb Company (US), Eli Lilly and Company (US), F. Hoffmann-La Roche Ltd (Switzerland), Johnson & Johnson Services, Inc. (US), Novartis AG (Switzerland), Otsuka Holdings Co., Ltd. (Japan), Pfizer Inc. (US), and others.
5  MARKET FACTOR ANALYSIS

6  GLOBAL DEPRESSION SCREENING MARKET, BY DISEASE TYPE

7  GLOBAL DEPRESSION SCREENING MARKET, BY DIAGNOSIS

8  GLOBAL DEPRESSION SCREENING MARKET, BY TREATMENT

9  GLOBAL DEPRESSION SCREENING MARKET, BY END USER

10  GLOBAL DEPRESSION SCREENING MARKET, BY REGION

11  COMPANY SHARE ANALYSIS

12  COMPANY PROFILES: TOP 7 PLAYERS

13  LIST OF TABLES

14  LIST OF FIGURES